Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 4:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2449–2472 of 2,671 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control II Clear all

Conditions: Locally Advanced Rectal Cancer
Interventions: Peposertib 50 mg, Peposertib 100 mg, Peposertib 150 mg, Peposertib 250 mg, Capecitabine, Radiotherapy (RT); Drug · Radiation
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 10
States / cities: Aurora, Colorado • New Haven, Connecticut • Great Neck, New York + 7 more

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Tiragolumab, Atezolizumab, Pemetrexed, Carboplatin, Cisplatin, Tiragolumab Matching Placebo, Pembrolizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 542 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 11
States / cities: Los Angeles, California • Whittier, California • Fort Myers, Florida + 8 more

Conditions: Prostate Adenocarcinoma
Interventions: Q-Urol, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Salt Lake City, Utah

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: afatinib, placebo; Drug · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 272
States / cities: Anchorage, Alaska • Little Rock, Arkansas • Fort Collins, Colorado + 186 more

Conditions: HIV-1 Infection
Interventions: Visbiome Extra Strength, Placebo; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 24
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more

Conditions: Hypertension
Interventions: Virtual Hypertension Clinic; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 25 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Breast Cancer
Interventions: AeroForm Tissue Expander; Device
Lead sponsor: AirXpanders, Inc.; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 8
States / cities: Greenbrae, California • San Jose, California • Fort Lauderdale, Florida + 4 more

Conditions: Sequelae of Viral Hepatitis, Transplantation Infection, Evidence of Liver Transplantation
Interventions: Hepatitis C Immune Globulin Intravenous (Human) 5%; Biological
Lead sponsor: ADMA Biologics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 3
States / cities: Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Lebrikizumab, Pirfenidone, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 40 Years and older
Enrollment: 505 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 54
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 47 more

Conditions: Peripheral Artery Disease (PAD)
Interventions: Ticagrelor, Comparator; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 50 Years to 130 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: Daytona Beach, Florida • Jacksonville, Florida • Ocala, Florida + 7 more

Conditions: Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Oligodendroglioma, Recurrent Brain Neoplasm, Recurrent Glioblastoma
Interventions: Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study, Placebo Administration, Trebananib; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 243
States / cities: Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 172 more

Conditions: Bipolar Disorder I, Bipolar Disorder II, Major Depressive Episode
Interventions: SAGE-217, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 11
States / cities: Little Rock, Arkansas • Garden Grove, California • Lemon Grove, California + 8 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: abatacept, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 20
States / cities: Phonix, Arizona • Berkeley, California • Los Angeles, California + 17 more

Conditions: Caregiver, Malignant Head and Neck Neoplasm, Paranasal Sinus Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma, Stage I Hypopharyngeal Squamous Cell Carcinoma, Stage I Laryngeal Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Squamous Cell Carcinoma, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Hypopharyngeal Squamous Cell Carcinoma, Stage II Laryngeal Squamous Cell Carcinoma, Stage II Lip and Oral Cavity Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma, Stage III Laryngeal Squamous Cell Carcinoma, Stage III Lip and Oral Cavity Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IV Hypopharyngeal Squamous Cell Carcinoma, Stage IV Laryngeal Squamous Cell Carcinoma, Stage IV Lip and Oral Cavity Squamous Cell Carcinoma, Stage IV Oropharyngeal Squamous Cell Carcinoma, Stage IVA Hypopharyngeal Squamous Cell Carcinoma, Stage IVA Laryngeal Squamous Cell Carcinoma, Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Hypopharyngeal Squamous Cell Carcinoma, Stage IVB Laryngeal Squamous Cell Carcinoma, Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Hypopharyngeal Squamous Cell Carcinoma, Stage IVC Laryngeal Squamous Cell Carcinoma, Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal SCC, Recurrent Paranasal Sinus Squamous Cell Carcinoma
Interventions: Communication Intervention, Watch video, Module completion of the Prepare to Care kit, Quality-of-Life Assessment, Survey Administration, Salivary cortisol collection; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Other Fatty Acid Oxidation Disorders, Diabetes Mellitus, Insulin Resistance
Interventions: Lipid/heparin; Other
Lead sponsor: Temple University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Volunteer
Interventions: Gantenerumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Caregivers
Interventions: Video-based coping skills training with telephone coaching; Behavioral
Lead sponsor: Williams LifeSkills; Industry
Eligibility: Not listed
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Acquired Immunodeficiency Syndrome, HIV
Interventions: Provider Visit Incentive (PVI), Incentive Choice (IC); Behavioral
Lead sponsor: National Bureau of Economic Research, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Caregivers, Community Health Workers, Knowledge, Attitude, Self-Efficacy, Intentions, Health
Interventions: Intervention to Help Orient Men to Excel (IN-HOME), Supplying Useful Perimenopause Through Post-menopause Online Resources and Tools (SUPPORT); Behavioral · Other
Lead sponsor: KDH Research & Communication; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Odontoid Fracture
Interventions: Abaloparatide, Hard collar immobilization; Drug · Device
Lead sponsor: David Lunardini; Other
Eligibility: 50 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Brain and Central Nervous System Tumors
Interventions: Rapamycin, Surgery, Supportive Care; Drug · Procedure
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer, Cervical Cancer
Interventions: educational intervention, questionnaire administration; Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 959 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Nelfinavir mesylate; Drug
Lead sponsor: Agouron Pharmaceuticals; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 8
States / cities: Los Angeles, California • Orange, California • San Diego, California + 5 more

Conditions: Chronic Sinusitis, Ethmoidal
Interventions: Steroid-eluting sinus implant, Post-op standard of care; Combination Product · Other
Lead sponsor: Collin County Ear Nose & Throat; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Frisco, Texas

Search by objective public record fields.

Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer

A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer

Trial of Quercetin, Bromelain, Rye Flower Pollen & Papain on Reducing Severity of Radiation-Induced Prostatitis

Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence

Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers

Virtual Hypertension Clinic

AirXpanders AeroForm Tissue Expander System for Breast Reconstruction

Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation

A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR

Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors

A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis

Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Cancer

Fat Induced Insulin Resistance and Atherosclerosis

A Single-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Gantenerumab Following Subcutaneous (SC) Administration in Healthy Volunteers

Video-Based Coping Skills Training for Caregivers

A Commitment Device for Medication Adherence Among HIV Patients

Intervention to Help Orient Men to Excel (IN-HOME) Phase II Study

PTH Analog Type II Odontoid Fracture

Sirolimus in Treating Patients With Glioblastoma Multiforme

Breast and Cervical Cancer Educational Intervention for Latinas in Western New York

A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis

The PIO II Study: In-office Post-op Placement of a Steroid-eluting Sinus Implant